Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Mike M who wrote (1670)	11/29/1999 5:35:00 PM
From: Street Walker	Read Replies (2) \| Respond to of 5582

4th quarter earnings estimates (preliminary) These are very rough estimates: $9.5 million total sales (would be more but demand has exceeded production - sales to fill the 'demand' will go towards 1st quarter earnings; last release said "orders" are 5:1 increase). $2 million advertising plus expenses to Citadel $1 million in profit 13 cents earnings/share PROFIT =rough estimate for 4Q Let me remind new investors last year 4Q was a 29 cent LOSS. If there are any hedge funds or newsletters looking to get in on the ground floor of a turnaround situation, this is definately a candidate. 1 billion colds per year in the US is a lot to treat ! Management is doing all they can to increase production. There are roughly 6.1 Billion people in the world. The common cold is something most everyone catches a couple of times per year. This is a product everyone needs! The demand for Zicam just in the US has precluded filling the orders from other countries until the production capacity increases. Regards, S.W.